Read by QxMD icon Read


Kazuhiko Kawahara, Jun Minakuchi, Narushi Yokota, Hiroto Suekane, Kenji Tsuchida, Shu Kawashima
AIM: Erythropoiesis-stimulating agents (ESAs) are all effective for renal anaemia in patients with chronic kidney disease (CKD). However, it was reported that the haemoglobin (Hb) concentration decreases to 8.4 g/dL during the initial phase of dialysis despite treatment with recombinant human erythropoietin (rHuEPO). This study compared Hb at the initiation of dialysis among patients treated with three different ESAs (rHuEPO, darbepoetin alfa [DA], and a continuous erythropoietin receptor activator [CERA])...
December 2015: Nephrology
Kiyoto Koibuchi, Moriatsu Miyagi, Taichi Arai, Toshiyuki Aoki, Atsushi Aikawa, Ken Sakai
AIM: Erythropoiesis-stimulating agent (ESA) treatment during the predialysis period can be a strategy to reduce cardiac mortality soon after initiation of dialysis. In this study, we compared the efficacy of continuous erythropoietin receptor activator (CERA) and darbepoetin alfa (DA) in patients with chronic kidney disease (CKD) over 6 months prior to initiation of dialysis. METHODS: This study was a retrospective propensity score-matched study conducted at a single center in Japan that analyzed the effects of CERA and DA therapy on haemoglobin (Hb) changes, ESA resistance index (ERI) changes, and interval of ESA administration during a 6-month observation period prior to initiation of dialysis...
December 2015: Nephrology
A Vega, S Abad, U Verdalles, I Aragoncillo, K Velazquez, B Quiroga, V Escudero, J M López-Gómez
BACKGROUND: Anemia is a prevalent situation in patients with chronic kidney disease (CKD) and can be well managed with erythropoiesis-stimulating agents (ESAs). Continuous erythropoietin receptor activator (CERA) has a long half-life that allows to be administered once monthly. The lowest recommended dose for patients with non dialysis CKD is 120 μg per month. The objectives were to assess the efficacy of subcutaneous monthly dosing of CERA in CKD stages 4 and 5 not on dialysis, and to determine the equivalent dose to epoetin β and darbepoetin α...
October 2014: Hippokratia
Vicente Escudero-Vilaplana, Concepción Martínez-Nieto, Juan Manuel López-Gómez, Almudena Vega-Martínez, José María Bellón-Cano, María Sanjurjo-Sáez
BACKGROUND: Some publications have shown that equivalent doses of erythropoiesis-stimulating agents (ESA) defined on label differ from those effective in clinical practice. Therefore, real costs could vary from theoretical costs in the treatment of anaemia in chronic kidney disease (CKD). OBJECTIVES: To perform a cost-minimization analysis to establish the economic impact of the principal ESAs used in treating anaemia secondary to CKD in daily practice. SECONDARY OBJECTIVES: to determine patient-month cost based on the erythropoietin resistance index (ERI); to analyze the difference in cost between pre-dialysis and peritoneal dialysis (PD) patients; and to analyze the association between iron deposits and ESA cost...
June 2013: International Journal of Clinical Pharmacy
Elena Contro, Elisa Maroni, Emanuela Cera, Aly Youssef, Federica Bellussi, Gianluigi Pilu, Nicola Rizzo, Giuseppe Pelusi, Tullio Ghi
OBJECTIVE: To evaluate the outcome of pregnancies with second trimester unilaterally increased uterine artery resistance. STUDY DESIGN: Between January 2007 and December 2009 all low-risk patients with unilateral increase of uterine artery pulsatility index (PI) but normal mean pulsatility at 20-22 weeks of gestation were included in the study group. Among these, cases with central placenta (group A) were distinguished from those with lateral placenta (group B)...
December 2010: European Journal of Obstetrics, Gynecology, and Reproductive Biology
L La Vecchia, M Bottero, P Centofante, F Bedogni, R Ometto, A Cera, A Fortunato
METHODS: Sixteen patients (15 males, 1 female; mean age 63 years, range 45-78) with severe heart failure (NYHA class III = 5; class IV = 11) secondary to ischemic heart disease (8), dilated cardiomyopathy (5) and valvular heart disease (3), were evaluated for eligibility to intermittent Dobutamine (D) treatment. As a part of this evaluation, they were submitted to an acute dose-ranging test with D, up to 10 micrograms/Kg/min under hemodynamic and electrocardiographic monitoring. By inclusion criteria, all patients had:-cardiac index (CI) < 2...
August 1996: Giornale Italiano di Cardiologia
E Clemente, R Solli, V Mei, R Cera, G Caramia, V Carnelli, E Ruffini, V Venturoli, A Corsini
The activity of pidotimod ((R)-3-[(S)-(5-oxo-2-pyrrolidinyl) carbonyl]-thiazolidine-4-carboxylic acid, PGT/1A, CAS 121808-62-6) was studied vs. placebo in a double-blind, randomized, multicentre trial, involving 60 pediatric patients with recurrent urinary tract infections. Recovery from acute events was quicker with pidotimod than with placebo (9.6 vs. 12.3 days). In treated patients antibiotic therapy was shorter (6.9 vs. 8.3 days) and main symptomatic parameters (body temperature, vesical tenesmus, stranguria, pollakiuria, total number of symptoms, total symptomatic intensity, rate of asymptomatic patients, haematuria, leukocyturia, positive urinary culture) receded quickly...
December 1994: Arzneimittel-Forschung
G Caramia, E Clemente, R Solli, V Mei, R Cera, V Carnelli, V Venturoli, A Corsini
The activity of pidotimod ((R)-3-[(S)-(5-oxo-2-pyrrolidinyl) carbonyl]-thiazolidine-4-carboxylic acid, PGT/1A, CAS 121808-62-6) was evaluated in a double-blind, placebo-controlled, randomized, multicentre trial, on 120 pediatric patients affected by recurrent respiratory infections. The clinical course of acute infections was favourable both in placebo and in treatment group, but recovery was quicker with pidotimod than with placebo. Antibiotic therapy and time of hospitalization were shorter in the patients taking pidotimod, and main symptomatic parameters (pharyngalgia, dysphagia, mucous membrane inflammation, adenopathy, anorexia) receded quickly...
December 1994: Arzneimittel-Forschung
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"